AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33904666 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular flushing with double lumen needles (Wallace DNS1733)
Number of subjects: 208
Study 33904666 — intervention group
Group type: COMPARATOR
Intervention: Direct aspiration with single lumen needles (Wallace ONS1733)
Number of subjects: 208
Study 33904666 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular flushing
Number of subjects: 208
Study 33904666 — intervention group
Group type: COMPARATOR
Intervention: Direct aspiration
Number of subjects: 208
Study 35875695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocapsiate (12 mg)
Number of subjects: 24
Study 35875695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32452284 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive hip joint mobilization
Number of subjects: 18
Study 32452284 — intervention group
Group type: COMPARATOR
Intervention: Placebo mobilization
Number of subjects: 18
Study 35172775 — intervention group
Group type: EXPERIMENTAL
Intervention: PROLACT intervention
Number of subjects: 434
Study 35172775 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 434
Study 33954881 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced violence screening model
Number of subjects: 2621
Study 33954881 — intervention group
Group type: COMPARATOR
Intervention: Routine screening
Number of subjects: 2621
Study 32512248 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐PDT
Number of subjects: 60
Study 32512248 — intervention group
Group type: COMPARATOR
Intervention: CPG
Number of subjects: 60
Study 36152013 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cultured epidermal cell suspension (ECS)
Number of subjects: 74
Study 36152013 — intervention group
Group type: COMPARATOR
Intervention: Hair follicle cell suspension (HFCS)
Number of subjects: 74
Study 36152013 — intervention group
Group type: EXPERIMENTAL
Intervention: ECS
Number of subjects: 74
Study 36152013 — intervention group
Group type: COMPARATOR
Intervention: HFCS
Number of subjects: 74
Study 33215986 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month recall
Number of subjects: 2372
Study 33215986 — intervention group
Group type: EXPERIMENTAL
Intervention: risk-based recall
Number of subjects: 2372
Study 33215986 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month recall
Number of subjects: 2372
Study 34236011 — intervention group
Group type: EXPERIMENTAL
Intervention: GB222 (1 mg/kg)
Number of subjects: 84
Study 34236011 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1 mg/kg)
Number of subjects: 84
Study 34236011 — intervention group
Group type: EXPERIMENTAL
Intervention: GB222
Number of subjects: 84
Study 34236011 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 84
Study 33471112 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 25
Study 33471112 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting golimumab treatment
Number of subjects: 25
Study 33471112 — intervention group
Group type: COMPARATOR
Intervention: Step-down strategy to MTX monotherapy
Number of subjects: 25
Study 35724518 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced single-theme CWLs with varying textual and pictorial components
Number of subjects: 523
Study 35724518 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced single-theme CWLs with pictorial components
Number of subjects: 523
Study 35724518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorially enhanced CWLs
Number of subjects: 523
Study 35724518 — intervention group
Group type: COMPARATOR
Intervention: Currently required CWLs in California
Number of subjects: 523
Study 33832100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 78
Study 33832100 — intervention group
Group type: COMPARATOR
Intervention: Hair shaving
Number of subjects: 78
Study 35552463 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 35
Study 32241619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796
Study 32241619 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study 35328990 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid and hyaluronic acid-based gel
Number of subjects: 40
Study 35328990 — intervention group
Group type: COMPARATOR
Intervention: Control group (no product used)
Number of subjects: 40
Study 32100647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient (1 g DHA, 160 mg EPA, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20 mg d‐α tocopherol, 1 mg folic acid and 20 g vitamin B12 per day)
Number of subjects: 51
Study 32100647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient and exercise (spin class twice per week)
Number of subjects: 51
Study 32100647 — intervention group
Group type: COMPARATOR
Intervention: Exercise and placebo
Number of subjects: 51
Study 32100647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 34807983 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX
Number of subjects: 123
Study 34807983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 32792079 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP 80/85 to 100 mm Hg target
Number of subjects: 120
Study 32792079 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of norepinephrine and dobutamine
Number of subjects: 120
Study 32792079 — intervention group
Group type: COMPARATOR
Intervention: MAP 65 mm Hg target
Number of subjects: 120
Study 32792079 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional pharmacologic support
Number of subjects: 120
Study 32792079 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival with good neurologic outcome at 180 days
Number of subjects: 120
Study 36321193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Breast Examination (CBE)
Number of subjects: 59447
Study 36321193 — intervention group
Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 59447
Study 33656786 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium AMF availability
Number of subjects: 0
Study 33656786 — intervention group
Group type: EXPERIMENTAL
Intervention: High AMF availability
Number of subjects: 0
Study 33656786 — intervention group
Group type: COMPARATOR
Intervention: Zero AMF availability
Number of subjects: 0
Study 33656786 — intervention group
Group type: EXPERIMENTAL
Intervention: AMF availability
Number of subjects: 0
Study 32416385 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic preventative intervention focused on reduction of safety aids
Number of subjects: 69
Study 32416385 — intervention group
Group type: COMPARATOR
Intervention: Health focused control group
Number of subjects: 69
Study 35320813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-pressure resistance training (TPRT) for 20 min/day in addition to traditional swallowing rehabilitation for 30 min/day for 4 weeks
Number of subjects: 0
Study 35320813 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing rehabilitation for 30 min/day for 4 weeks
Number of subjects: 0
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPEER 1
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPEER 2
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPEER 3
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPEER 1-2
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal PDAC
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: No surgery
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients
Number of subjects: 257
Study 32785768 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 257
Study 35985545 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV+BRC
Number of subjects: 1000
Study 35985545 — intervention group
Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 1000
Study 35985545 — intervention group
Group type: COMPARATOR
Intervention: ETV+BRC and ETV monotherapy
Number of subjects: 1000
Study 34732148 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention (60-min sessions, twice a week for 6 months)
Number of subjects: 43
Study 34732148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 32744872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention for test anxiety (six sessions)
Number of subjects: 0
Study 32744872 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 33270707 — intervention group
Group type: EXPERIMENTAL
Intervention: Kola genotypes (A12, JB4, JB19, JB36, P2-1b, P2-1c) identified for phenolic traits selection
Number of subjects: 25
Study 33270707 — intervention group
Group type: EXPERIMENTAL
Intervention: Kola genotypes (A10, Club, Atta1, JB10) identified for soluble and insoluble sugar-rich variety development
Number of subjects: 25
Study 36104016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 226
Study 32392574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 51
Study 32392574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 32481369 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal adductor canal block (PACB)
Number of subjects: 0
Study 32481369 — intervention group
Group type: COMPARATOR
Intervention: Distal adductor canal block (DACB)
Number of subjects: 0
Study 36344827 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational booklet with 4-session support intervention
Number of subjects: 66
Study 36344827 — intervention group
Group type: COMPARATOR
Intervention: Informational booklet without 4-session support intervention
Number of subjects: 66
Study 35080127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved bioactive split thickness skin allograft (BSA)
Number of subjects: 100
Study 35080127 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC, collagen alginate dressing)
Number of subjects: 100
Study 34323596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dileucine (2g)
Number of subjects: 10
Study 34323596 — intervention group
Group type: COMPARATOR
Intervention: Leucine (2g)
Number of subjects: 10
Study 33283151 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable technology (Fitbit Charge 2) with personalised text message feedback and goal setting
Number of subjects: 0
Study 33283151 — intervention group
Group type: COMPARATOR
Intervention: Wearable technology (Fitbit Charge 2) without feedback (active comparator)
Number of subjects: 0
Study 33283151 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups will be re-assessed at 12 weeks and 24 weeks
Number of subjects: 0
Study 36047026 — intervention group
Group type: EXPERIMENTAL
Intervention: No drain
Number of subjects: 90
Study 36047026 — intervention group
Group type: COMPARATOR
Intervention: Drain
Number of subjects: 90
Study 33107209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (12-week training and exercise program including walking sessions at home at least three times a week)
Number of subjects: 70
Study 33107209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 33107209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program
Number of subjects: 70
Study 33107209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 33915788 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified low-protein formula (mLP) (1.7 g protein/100 kcal)
Number of subjects: 133
Study 33915788 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CTRL) (2.1 g protein/100 kcal)
Number of subjects: 133
Study 33915788 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed (BF)
Number of subjects: 133
Study 32406265 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep Safe intervention
Number of subjects: 100
Study 33306026 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink Less app with daily 11 AM notification
Number of subjects: 19233
Study 33306026 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink Less app
Number of subjects: 19233
Study 35128872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-penetrating needling technique of acupuncture and enema with tuihuang mixture
Number of subjects: 120
Study 35128872 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine treatment and enema with tuihuang mixture
Number of subjects: 120
Study 32092472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bambuterol hydrochloride (10 mg, once daily, for 3 days)
Number of subjects: 42
Study 32092472 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 42
Study 35383114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg Q2W)
Number of subjects: 243
Study 35383114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg Q2W)
Number of subjects: 243
Study 35383114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg Q3W for four doses then nivolumab 240 mg Q2W)
Number of subjects: 243
Study 35383114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 34634097 — intervention group
Group type: EXPERIMENTAL
Intervention: SPELL (base intervention)
Number of subjects: 7076
Study 34634097 — intervention group
Group type: EXPERIMENTAL
Intervention: SPELL+PD (enhanced version with professional development for teachers)
Number of subjects: 7076
Study 34634097 — intervention group
Group type: EXPERIMENTAL
Intervention: SPELL+HOME (enhanced version with home-based program for parents)
Number of subjects: 7076
Study 34634097 — intervention group
Group type: COMPARATOR
Intervention: BAU (business as usual)
Number of subjects: 7076
Study 34634097 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation analyses for children with mothers having low-mid education
Number of subjects: 7076
Study 32300055 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised, trauma-informed yoga (n=10)
Number of subjects: 21
Study 32300055 — intervention group
Group type: COMPARATOR
Intervention: Group-format fitness (n=8)
Number of subjects: 21
Study 34185752 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counseling combined with outdoor exercise
Number of subjects: 160
Study 34185752 — intervention group
Group type: COMPARATOR
Intervention: Routine in-campus education of health knowledge
Number of subjects: 160
Study 34797038 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only psychoeducational intervention
Number of subjects: 86
Study 34797038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on parent training in a naturalistic developmental intervention
Number of subjects: 86
Study 34091607 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised core stability exercise programme
Number of subjects: 30
Study 34091607 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised, home-based core stability exercise programme
Number of subjects: 30
Study 33293804 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point of care guided approach
Number of subjects: 386
Study 33293804 — intervention group
Group type: COMPARATOR
Intervention: Sputum color assessment
Number of subjects: 386
Study 35055470 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention program to foster resilience over eight weeks
Number of subjects: 72
Study 35055470 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 72
Study 33396887 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined serum 25(OH)D
Number of subjects: 307618
Study 33396887 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to depression
Number of subjects: 307618
Study 33396887 — intervention group
Group type: COMPARATOR
Intervention: Higher 25(OH)D concentrations
Number of subjects: 307618
Study 36117204 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy combined with HILT (n=14)
Number of subjects: 42
Study 36117204 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy combined with ESWT (n=14)
Number of subjects: 42
Study 36117204 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone (n=14)
Number of subjects: 42
Study 33763127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration applied to MCPJ digit 3 at 60 Hz and amplitude of 2 mm
Number of subjects: 19
Study 33763127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration applied to MCPJ digit 5
Number of subjects: 19
Study 33763127 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% supramaximal stimulus intensity
Number of subjects: 19
Study 33763127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of vibration stimulation
Number of subjects: 19
Study 34383222 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 7% sodium chloride solution
Number of subjects: 644
Study 34383222 — intervention group
Group type: COMPARATOR
Intervention: Control group (coughing up sputum as usual)
Number of subjects: 644
Study 32071118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelipepimut-S (NPS) with GM-CSF
Number of subjects: 275
Study 32071118 — intervention group
Group type: COMPARATOR
Intervention: Placebo with GM-CSF (control)
Number of subjects: 275
Study 616389246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oro-Pharyngeal airway cap (OPLAC)
Number of subjects: 86
Study 616389246 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETT)
Number of subjects: 86
Study 35803723 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 299
Study 33587897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Number of subjects: 84
Study 33587897 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid
Number of subjects: 84
Study 33587897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline plus Delamanid
Number of subjects: 84
Study 32249850 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lutein supplementation (beeswax group)
Number of subjects: 39
Study 32249850 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lutein supplementation (glycerol fatty acid esters group)
Number of subjects: 39
Study 32249850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (beeswax and glycerol fatty acid esters)
Number of subjects: 39
Study 32249850 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of green vegetables
Number of subjects: 39
Study 32249850 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 39
Study 34274687 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Stepping Exercise (ISE)
Number of subjects: 14
Study 34274687 — intervention group
Group type: COMPARATOR
Intervention: Home Exercise Program (Control)
Number of subjects: 14
Study 32363411 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS program (intervention group)
Number of subjects: 280
Study 32363411 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 35378068 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg by subcutaneous injection every 2 weeks)
Number of subjects: 18924
Study 35378068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 35378068 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 34015046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led anticipatory care planning intervention
Number of subjects: 34
Study 34015046 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 34
Study 32758455 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio 1143 (200 mg per day on days 1-14 of 21-day cycles, for three cycles)
Number of subjects: 96
Study 32758455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mg/mL, administered at the same dosing schedule)
Number of subjects: 96
Study 32758455 — intervention group
Group type: EXPERIMENTAL
Intervention: Debio 1143
Number of subjects: 96
Study 32758455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 35421030 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpose-design underpants
Number of subjects: 31
Study 35421030 — intervention group
Group type: COMPARATOR
Intervention: Conventional underpants
Number of subjects: 31
Study 34454572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilavembu Kudineer (NVK)
Number of subjects: 125
Study 34454572 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaba Sura Kudineer (KSK)
Number of subjects: 125
Study 34454572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decaffeinated tea)
Number of subjects: 125
Study 34454572 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (NVK, KSK, and placebo)
Number of subjects: 125
Study 35803632 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA)
Number of subjects: 0
Study 35803632 — intervention group
Group type: COMPARATOR
Intervention: School-based deworming (SBD)
Number of subjects: 0
Study 33431147 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex school-based intervention
Number of subjects: 40
Study 33431147 — intervention group
Group type: COMPARATOR
Intervention: Control (current practice)
Number of subjects: 40
Study 34144489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriomas with peritoneal endometriosis
Number of subjects: 310
Study 34144489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriomas with deep infiltrating endometriosis
Number of subjects: 310
Study 34144489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriomas with both peritoneal and deep infiltrating endometriosis
Number of subjects: 310
Study 34144489 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral endometriomas
Number of subjects: 310